Citi Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

In a report released on August 27, from Citi maintained a Buy rating on Hansoh Pharmaceutical Group Company Limited, with a price target of HK$52.00. The company’s shares closed yesterday at HK$36.82.

Currently, the analyst consensus on Hansoh Pharmaceutical Group Company Limited is a Strong Buy with an average price target of HK$46.40, representing a 26.02% upside. In a report released on August 18, CMB International Securities also maintained a Buy rating on the stock with a HK$47.19 price target.

Based on Hansoh Pharmaceutical Group Company Limited’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$7.59 billion and a net profit of HK$2.42 billion. In comparison, last year the company earned a revenue of HK$5.76 billion and had a net profit of HK$1.65 billion